Table 3.
Main characteristics of patients with atypical hemolytic uremic syndrome who relapsed or not after eculizumab discontinuation
| Patient Characteristics | Relapsers, n=12 | Nonrelapsers, n=26 | P Value |
|---|---|---|---|
| Women | 7 (58) | 17 (65) | 0.95 |
| Age, yr | |||
| Adults | 25 (20–37) | 36 (21–79) | 0.02 |
| Children | 6 (2–9) | 9 (5–17) | 0.45 |
| Patients with ≥1 aHUS episode before eculizumab use | 6 of 12 (50) | 3 of 26 (11) | 0.03 |
| HD at onset | 6 of 12 (50) | 12 of 26 (46) | 0.89 |
| Duration of eculizumab treatment, mo | 14 (2–50) | 14.5 (3–45) | 0.95 |
| SCr at eculizumab discontinuation, mg/dl | |||
| Adults | 1 (0.76–1.1) | 1 (0.65–2.8) | 0.55 |
| Children | 0.4 (0.25–0.45) | 0.42 (0.4–0.44) | 0.90 |
| Variants | |||
| CFH | 8 (67) | 3 (11) | 0.002 |
| MCP | 4 (33) | 4 (15) | 0.20 |
| No variant | 0 | 16 (62) | <0.001 |
| Follow-up after eculizumab discontinuation, mo | 21.5 (15–38) | 21.1 (5–43) | 0.96 |
Values are shown as n (%) or as median (full range). aHUS, atypical hemolytic uremic syndrome; HD, hemodialysis; SCr, serum creatinine; CFH, complement factor H; MCP, membrane cofactor protein.